Haemonetics Beats Expectations in Q3 Earnings

Haemonetics, a blood products specialist, reported robust Q3 earnings, surpassing Wall Streets expectations with a non-GAAP profit per share of $1.27, a 14% increase. Despite a slight revenue dip, the company raised its full-year adjusted earnings per share guidance to $4.09, and improved its operating margin to 17.9%. Free cash flow margin also saw a significant boost, rising to 32.5%. The stock responded positively, trading up by 12.8% to $57.23.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.